Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413089 | 1.00 | CA2 (0.46) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL10304985 | 1.00 | CA2 (0.46) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL18817541 | 0.88 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL7154999 | 0.88 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL13637952 | 0.87 | ALDH1A1 (0.43) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL10065754 | 0.87 | ALDH1A1 (0.43) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL10972837 | 0.85 | ALDH1A1 (0.52) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL12059431 | 0.85 | ALDH1A1 (0.52) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL13130046 | 0.84 | CA2 (0.47) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL10974424 | 0.84 | ALDH1A1 (0.55) | CA2ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-25 | — | — | US | disclosed |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-10-17 | — | — | US | disclosed |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-08-10 | — | — | US | disclosed |
| WO-2023143988-A1 | NEW COMPOUNDS AND THEIR USE AS ANTI-AGING AGENT OR AS EXERCISE ENHANCER | ETH ZURICH (CH) | 2023-08-03 | — | — | WO | disclosed |
| US-20230244149-A1 | COMPOSITION FOR FORMING SILICON-CONTAINING RESIST UNDERLAYER FILM AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-03 | — | — | US | disclosed |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| US-9989849-B2 | Chemically amplified resist material and resist pattern-forming method | JSR CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9878042-B2 | Lipid formulations for delivery of therapeutic agents to solid tumors | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2018-01-30 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-7662845-B2 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12 | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090192320-A1 | MODIFIED BIO-RELATED SUBSTANCE, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATE | NOF CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-7524875-B2 | Modified bio-related substance, process for producing the same, and intermediate | NOF CORPORATION (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-7354940-B2 | 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| WO-2004024060-A2 | METALLOPROTEINASE INHIBITORS AND INTERMEDIATES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192320-A1 | MODIFIED BIO-RELATED SUBSTANCE, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATE | BMP1, BMP2, AQP1 | CA2 827/4885ALDH1A1 106/4885NPSR1 184/4885 |
| US-20090292120-A1 | BENZIMIDAZOLE COMPOUNDS HAVING GASTRIC ACID SECRETION INHIBITORY ACTION | GIPR, HRH2, SI | CA2 108/4885ALDH1A1 180/4885NPSR1 1979/4885 |
| US-20230248831-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS | PNLIP, NPC1L1, CETP | CA2 3725/4885ALDH1A1 2161/4885NPSR1 2165/4885 |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | ETV6, PKD1, PKD2 | CA2 3097/4885ALDH1A1 3150/4885NPSR1 3756/4885 |
| US-11786598-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | CA2 3625/4885ALDH1A1 1878/4885NPSR1 2451/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | CA2 2254/4885ALDH1A1 3137/4885NPSR1 3749/4885 |
| US-20180071397-A1 | NOVEL LIPID FORMULATIONS FOR DELIVERY OF THERAPEUTIC AGENTS TO SOLID TUMORS | PNLIP, CETP, NPC1L1 | CA2 3638/4885ALDH1A1 2057/4885NPSR1 2497/4885 |
| US-12016929-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | CA2 3625/4885ALDH1A1 1878/4885NPSR1 2451/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | CA2 4828/4885ALDH1A1 1582/4885NPSR1 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.